Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Michael Chi sold 7,500 shares of the company’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the transaction, the insider now owns 193,980 shares in the company, valued at $4,306,356. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Michael Chi also recently made the following trade(s):
- On Thursday, August 1st, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $45,188.00.
Hims & Hers Health Stock Down 9.4 %
Shares of Hims & Hers Health stock opened at $21.38 on Thursday. The firm has a market cap of $4.59 billion, a PE ratio of 267.22 and a beta of 1.06. The company’s fifty day simple moving average is $17.24 and its two-hundred day simple moving average is $17.73. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74.
Analysts Set New Price Targets
HIMS has been the subject of a number of research reports. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Piper Sandler reissued a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and an average price target of $20.21.
View Our Latest Analysis on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after acquiring an additional 273,473 shares during the period. Finally, M&G Plc bought a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $8,232,000. Institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- The 3 Best Retail Stocks to Shop for in August
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Average Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.